Compare United States Brent Oil Fund LP (BNO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Brent Oil Fund LP vs ResMed Inc. — how do they compare? United States Brent Oil Fund LP trades at $47.24, while ResMed Inc. trades at $193 (market cap $28.00B). The key difference: ResMed Inc. pays a 1.24% dividend while United States Brent Oil Fund LP pays none, and United States Brent Oil Fund LP is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| BNO | RMD | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $293.73 |
52-Week Low | $27.20 | $182.82 |
Market Cap | — | $28.00B |
Enterprise Value | — | $27.18B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNO, a US-listed oil-focused stock, trades at $46.00, up 9.13% on the day, driven by escalating Middle East tensions that have pushed crude prices to one-month highs. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI at 86 suggests overbought conditions. Recent news highlights supply risks from U.S.-Iran hostilities, including blockades and strikes, which are boosting energy sector sentiment and driving volatility.
The outlook for BNO remains heavily tied to geopolitical developments and oil price momentum. Upside potential exists if supply disruptions persist, but risks include rapid de-escalation or demand weakness. Investors should weigh the stock's sensitivity to crude fluctuations against current bullish technical and sentiment signals.
ResMed (RMD) trades at $198.50, down 2.63% on the day, with technical indicators showing a bearish trend near support at $197. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $2.86 versus $2.80 expected, and robust profitability with a 27.44% net margin. Recent strategic moves include the sale of its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets.
The outlook remains positive given analyst consensus targets near $249.57, representing significant upside, though near-term technical weakness and competitive pressures in digital health pose risks. Revenue growth is projected to reach $5.5 billion in 2026, supporting a solid investment case for long-term holders despite current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
